Linvoseltamab-gcpt

iStock, Oleksii Liskonih After inking a T cell engager pact with Chimagen Biosciences a few years ago, GSK is back for more, this time acquiring a multiple myeloma program from the antibody specialist. GSK is picking up a preclinical trispecific T cell engager from China biotech Chimagen Biosciences in a deal that could reach up to $750 million. The British pharma will pay an undisclosed upfront fee for full global rights to the candidate, which is expected to enter the clinic for multiple myeloma next year, according to a Tuesday release . Chimagen will have the chance to collect undisclosed development and commercial milestone payments for a potential deal value total of up to $750 million. This is the second time GSK has nabbed a pipeline program from Chimagen, following a 2024 deal worth up to $850 million that centered on a separate T cell engager (TCE) that targets B cell-mediated conditions. GSK said its newly acquired TCE—which is designed to target T cells and two tumor antigens—can potentially provide differentiated efficacy and a better safety pro to current TCEs. Approved TCEs for multiple myeloma include Johnson & Johnson’s Tecvayli and Talvey, Regeneron’s Lynozyfic and Pfizer’s Elrexfio. All four are bispecific antibodies that carry boxed warnings for cytokine release syndrome and neurologic toxicity. GSK is hoping the trispecific candidate from Chimagen will help boost adoption and earlier use for patients with multiple myeloma. “The agreement complements our existing portfolio in multiple myeloma, adding a new potential option to address the different needs of patients facing this complex disease,” Hesham Abdullah, GSK global head of oncology and R&D, said in a prepared statement. Lung cancer Summit, BioNTech, more headline WCLC with next-gen lung cancer drugs BioNTech, Summit Therapeutics, GSK and Roche have made a splash at the ongoing World Conference on Lung Cancer taking place in South Korea. These companies and their partners have all shared new findings for their closely watched programs, highlighting overall survival benefits in various types of lung cancer. September 14, 2026 · 4 min read · Gabrielle Masson Read more The pact builds on GSK’s 2024 deal with Chimagen, when the pharma paid $300 million upfront and offered $550 million in biobucks for CMG1A46, a clinical-stage bispecific TCE that targets CD19 and CD20. The program is currently in Phase 1 trials for B cell malignancies and B cell dependent autoimmune disorders, according to GSK. GSK’s oncology pipeline also includes the late-stage asset risvutatug rezetecan (ris-rez), a B7-H3-targeted antibody-drug conjugate being developed with China’s Hansoh Pharma. Over the weekend, the partners shared that ris-rez was tied to a median OS of 18.5 months in relapsed small cell lung cancer—a 54% reduced death risk compared with standard-of-care. In December 2023, the U.K. pharma paid $185 million to secure exclusive global rights to ris-rez outside of China, Hong Kong, Macau and Taiwan, and additional payments could bring that deal’s total as high as $1.7 billion. News of the new Chimagen pact also follows on the heels of reports of 650 staffers laid off at GSK. The job cuts are related to a vaccine manufacturing site closure, with the company consolidating its efforts to one site in Canada. In July, the pharma announced a sweeping restructure designed to save about $2.5 billion over the next three years, with the expected savings designed to buoy its portfolio and late-stage pipeline. Earnings GSK shares rise as $2.5B cost-cutting plan unveiled As GSK records $2.4 billion in impairment charges for the second quarter, the U.K. pharma has announced a sweeping restructure designed to save about the same amount of money over the next few years. July 28, 2026 · 4 min read · Gabrielle Masson Read more

Dive Brief:AbbVie said its dual-acting drug for multiple myeloma met the main goal of a Phase 3 clinical trial, helping people whove progressed on two or more lines of therapy survive longer without progression than those who received standard treatment regimens, the company said Thursday.The drug, called etentamig, could be safer than rival drugs launched by Johnson & Johnson, Pfizer and Regeneron, with low rates of two kinds of serious immune responses common to other drugs of its type. AbbVie said its safety profile could enable greater use in community oncology centers because of reduced need for post-treatment patient monitoring.Etentamig is a type of drug called a bispecific antibody that can simultaneously bind to diseased tumor cells and T cells, triggering an immune response to fight multiple myeloma. It trails by more than four years the first drug in its class, J&Js Tecvayli, which booked $462 million in sales through the first six months of 2026.Dive Insight:Immunotherapy has reshaped care across nearly every type of cancer, and the blood cancers like leukemia, lymphoma and multiple myeloma have been part of that transformation. In blood cancers, it first started with a type of engineered cell treatment called CAR-T therapy, and dual-acting bispecific antibodies have followed closely behind.Bispecific antibodies have an advantage against CAR-T therapies, which require extensive re-engineering of patients own cells to fight cancer. But they still carry some of the same safety issues, specifically immune responses called cytokine release syndrome and a neurological condition called ICANS, which have required similar post-treatment monitoring protocols that patients who receive CAR-T therapies have to undergo.Oncologists have been refining those monitoring protocols to enable more patients to bypass inpatient stays, such as giving them their own tools to monitor symptoms as well as preventive treatments. A drug with reduced side effects could have an edge, however.AbbVies trial enrolled 421 people with multiple myeloma, and randomized half to get etentamig. Independent trial monitors detected a significant difference between the two groups at a pre-planned interim checkpoint, prompting investigators to unblind the trial, leaving 393 people evaluable at an average of 11 months after trial entry.On efficacy,etentamig reduced the risk of progression or death by 60% compared with standard therapies, and stimulated a response in 74% of the enrollees who got it, significantly more than the 46% of those on standard therapies who responded, AbbVie said.On safety, 28% got CRS in the etentamig group, and only one got ICANS. By comparison, in clinical trials nearly three-quarters of Tecvayli patients got CRS, along with more than half of people who received Pfizers Elrexfio and 46% of those who got Regenerons Lynozyfic.Most participants in AbbVies trial who developed CRS also only experienced a mild form of the immune response.The profile gives etentamig the potential to provide access across a range of treatment settings beyond specialized treatment centers and into outpatient and community-based settings, said Peter Voorhees, a trial investigator and chief of the plasma cell disorders division at Atrium Health Levine Cancer Institute, in a statement provided by AbbVie.AbbVie said it will discuss the trial results with regulators and present the data later this month at the International Myeloma Society Annual Meeting. '